Synergistic enhancement of PARP inhibition via small molecule UNI66-mediated suppression of BRD4-dependent transcription of RAD51 and CtIP
NAR Cancer · 02.04.2025 · 7 (2)
DOI: 10.1093/narcan/zcaf013 ↗Kurz gefasst
Fachartikel in der Zeitschrift NAR Cancer, online erschienen am 30.04.2025. Verfasst von Enkhzul Amarsanaa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genomic Integrity, Institute for Basic Science, Ulsan 44919, Republic of Korea. Hauptthemen laut MEDLINE: Poly(ADP-ribose) Polymerase Inhibitors, Transcription Factors, Rad51 Recombinase, Cell Cycle Proteins. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institute for Basic Science.
Abstract (Originalsprache)
Targeted therapy leveraging synthetic lethality in homologous recombination (HR)-defective tumors, particularly in BRCA-mutated tumors through poly(ADP-ribose) polymerase (PARP)-dependent repair inhibition, has shown success. However, the challenge lies in the ability of the tumors to reactivate HR via diverse mechanisms, leading to resistance against PARP-dependent repair inhibition. Addressing this issue, the down-regulation of HR activity has been explored as a potential strategy to overcome PARP inhibitor-resistant tumors. Yet, the intricate modulation of HR gene expression in mammalian cells is still not fully understood. In this study, we used a small molecule, UNI66, identified from high-throughput screening, to investigate regulatory mechanisms of HR. UNI66 was observed to induce synthetic lethality in PARP1-deficient cells and enhanced the sensitivity of multiple cancer cells to PARP inhibitors, suggesting a role in HR down-regulation. Mechanistically, UNI66 was found to interact with and inhibit BRD4 protein binding to the promoters of CtIP and RAD51 genes, resulting in the down-regulation of their transcription. This decrease in CtIP and RAD51 expression was associated with reduced HR activity, thereby increasing the sensitivity of tumors to PARP inhibitors. These findings indicate that BRD4-mediated transcriptional regulation of CtIP and RAD51 influences HR activity, which may have implications for overcoming resistance to PARP inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Genomic Integrity, Institute for Basic Science, Ulsan 44919, Republic of Korea.
- Department of Biological Sciences, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea.
- Department of Biomedical Engineering, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea.
- Clinical Research Institute, Kyung Hee University Hospital at Gangdong, School of Medicine, Kyung Hee University, Seoul 05278, Republic of Korea.
ORCID-Profile: Kyungjae Myung
Förderung
- Institute for Basic Science
Zitieren
APA
Amarsanaa, E., Wie, M., Shin, U., Bilal, N., Hwang, J., Lee, E. A., Lee, S. Y., Kim, B. G., Kim, S., Lee, Y., & Myung, K. (2025). Synergistic enhancement of PARP inhibition via small molecule UNI66-mediated suppression of BRD4-dependent transcription of RAD51 and CtIP. NAR Cancer, 7(2). https://doi.org/10.1093/narcan/zcaf013
Vancouver
Amarsanaa E, Wie M, Shin U, Bilal N, Hwang J, Lee EA, et al. Synergistic enhancement of PARP inhibition via small molecule UNI66-mediated suppression of BRD4-dependent transcription of RAD51 and CtIP. NAR Cancer. 2025;7(2). doi:10.1093/narcan/zcaf013
BibTeX
@article{Amarsanaa2025,
author = {Amarsanaa, Enkhzul and Wie, Minwoo and Shin, Unbeom and Bilal, Nabeela and Hwang, Jungme and Lee, Eun A and Lee, Seon Young and Kim, Byung-Gyu and Kim, Shinseog and Lee, Yoonsung and Myung, Kyungjae},
title = {Synergistic enhancement of PARP inhibition via small molecule UNI66-mediated suppression of BRD4-dependent transcription of RAD51 and CtIP},
journal = {NAR Cancer},
year = {2025},
volume = {7},
number = {2},
doi = {10.1093/narcan/zcaf013}
}
EUVIMED